People usually search for this
GLP-1 5mg
$150.00
Products will arrive in a lyophilized (powder) form for maximum stability
Semaglutide is a long-acting GLP-1 receptor agonist and the most extensively studied peptide in its class, with research spanning diabetes, obesity, cardiovascular, and kidney models. Its DPP-4-resistant design supports a ~7-day half-life and once-weekly dosing in preclinical protocols. The 5mg vial format suits shorter studies, supplied at ≥99% HPLC purity, for research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
Semaglutide
SYNONYMS
NN9535
CAS NUMBER
910463-68-2
MOLECULAR FORMULA
C187H291N45O59
MOLECULAR WEIGHT
~4113.58 g/mol
STRUCTURE
Peptide sequence with modifications to enhance stability; includes Aib at position 8, Arg at position 34, and a C18 fatty diacid moiety attached to lysine 26 via a hydrophilic spacer.
PEPTIDE SEQUENCE
H-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gln-Lys-Ala-Ala-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH?
CHEMICAL STRUCTURE
Source: PubChem
Mechanism of Action
Semaglutide is a potent, selective GLP-1 receptor agonist. It stimulates the GLP-1 receptor in pancreatic ?-cells to enhance glucose-dependent insulin secretion, suppresses pancreatic ?-cell glucagon secretion, and directly acts on appetite-regulating centers in the brain. The result is pronounced postprandial and fasting blood glucose reduction, delayed gastric emptying (transient), reduced hunger, enhanced satiety, and decreased caloric intake. Structural modifications protect against DPP-4 degradation and extend the peptide’s half-life, allowing once-weekly dosing
1
Pancreas: Enhanced glucose-dependent insulin secretion; glucagon suppression, lowering hepatic glucose output
2
Central Nervous System: Decreases food intake by targeting homeostatic and hedonic appetite pathways (hindbrain/hypothalamus), reducing hunger and cravings, and enhancing satiety
3
Gastrointestinal Tract: Delays gastric emptying, contributing to satiety (transient effect at higher doses)
4
Adiposity/Energy Intake: Weight loss is primarily driven by sustained reduction in caloric intake, not increased energy expenditure
Biological Activity
Potent GLP-1 receptor agonist Enhances insulin secretion (glucose-dependent) Suppresses glucagon secretion Reduces appetite and caloric intake Produces significant, sustained body weight loss Improves cardiometabolic risk factors (glycemia, blood pressure, lipids)
Storage
- Refrigerate once reconstituted. Protect from light and moisture.
Drug Categories
Amino Acids, Peptides, and Proteins; Lipids
Additional Notes
- Engineered for DPP-IV resistance and long half-life via fatty-acid conjugation
- Demonstrates the highest anti-obesity efficacy of any currently approved agent
Summary Table
Property
Description
CAS Number
910463-68-2
Molecular Formula
C187H291N45O5
Molecular Weight (MW)
~4113.58 g/mol
Mechanism of Action
GLP-1 receptor agonist; enhances insulin, suppresses glucagon, reduces appetite and energy intake
Biological Activity
Antidiabetic, anti-obesity; improves glycemic control, reduces weight and cardiometabolic risk factors
Supplied Form
Lyophilized powder (research use); solution for injection (clinical)
Purity
≥95% (HPLC)
Storage
-20°C to -80°C, dry, protected from light
Drug Categories
Amino Acids, Peptides, and Proteins; Lipids
Additional Notes
Modifications provide extended half-life for clinical formulation
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
Semaglutide is a modified GLP-1 analog containing 94% sequence homology with native human GLP-1. Key structural changes—Aib substitution at position 8, Arg at position 34, and C18 fatty diacid conjugation at Lys26—enable reversible albumin binding and confer resistance to DPP-4-mediated degradation. This results in a long half-life (approximately 7 days), making it suitable for once-weekly subcutaneous injection. Semaglutide robustly reduces appetite, promotes satiety, and significantly decreases body weight and glycemic parameters in both obese/overweight individuals and those with type 2 diabetes.
Research Highlights
Sustained Weight Loss: Reductions of 8–16%+ of baseline body weight over 1–2 years; 86% of patients lose at least 5% of baseline weight; up to 32% lose ?
20%
Glycemic Control: HbA1c reductions up to 1.
9% vs placebo, with effects on both fasting and postprandial glucose
Cardiometabolic Improvement: Decreases in blood pressure, waist circumference, lipid fractions, and inflammatory biomarkers; improved quality of life metrics
Head-to-Head Studies: Outperforms once-daily liraglutide 3.
0 mg, orlistat, phentermine–topiramate, and naltrexone–bupropion for weight loss efficacy
Pharmacokinetic Profile
Route of Administration
SC
Dosing Frequency
Once weekly
Half-Life
184 hours
- Route of Administration: Subcutaneous
- Dosing Frequency: Once weekly (subcutaneous)
- Half-Life: ~155–184 hours (6.5–7.7 days), supporting once-weekly SC dosing
- Formulation:
Formulation & Handling
- Reconstitute in sterile water or PBS (pH ~7.4) for in vivo/in vitro use
- Store at –20°C in aliquots to prevent freeze-thaw degradation
- Shelf-stable for 12 months under recommended storage condition
Clinical Trial Activity
Trial ID
Title
Phase
Study Type
Sponsor
NCT0354893
STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
3
Intervention
NN
NCT0355275
STEP 2: Semaglutide in Adults with Overweight/Obesity and Type 2 Diabetes
3
Intervention
NN
NCT0361158
STEP 3: Semaglutide plus Intensive Behavioral Therapy in Obesity
3
Intervention
NN
NCT0354898
STEP 4: Weight Loss Maintenance with Semaglutide
3
Intervention
NN
NCT04573528
SELECT: Semaglutide Effects on Heart Disease and Stroke in Obesity
3
Intervention
NN
References
1
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021). https://doi.org/10.1056/NEJMoa2032183
2
Davies, M. et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318, 1460–1470 (2017). https://doi.org/10.1001/jama.2017.14752
3
Lau, D. C. W., Batterham, R. L. & le Roux, C. W. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Rev. Clin. Pharmacol. 15, 251–268 (2022). https://doi.org/10.1080/17512433.2022.2070473
4
Rubino, D. et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325, 1414–1425 (2021). https://doi.org/10.1001/jama.2021.3224
5
Lambers Heerspink, H. J. et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat. Med. 31, 278–285 (2025). https://doi.org/10.1038/s41591-024-03327-6
6
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart Related products
Adipotide 5mg
Summary Description: Adipotide is a synthetic peptidomimetic that targets the vasculature of white adipose tissue, inducing rapid and significant weight loss through apoptosis of adipose endothelial cells. This compound is studied extensively in animal models for its anti-obesity effects and potential to improve metabolic parameters such as insulin sensitivity1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
BPC-157 10mg
Summary Description: BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a protein found in human gastric juice. In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties1-3. BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration4. Its chemical stability in gastric environments and efficacy across multiple administration routes make it a candidate for further investigation in regenerative pharmacology2.
Products will arrive in a lyophilized (powder) form for maximum stability
DSIP 10mg
Summary Description: Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring peptide known for its ability to support deep, restorative sleep and help balance the body’s stress and hormonal responses. Originally discovered in the 1970s from the blood of sleeping animals, DSIP has since been studied for its potential to promote slow-wave (deep) sleep, calm the nervous system, and support recovery. Studies suggest that DSIP works by helping the brain regulate its natural sleep rhythms and hormone balance, making it a promising peptide for overall rest, resilience, and well-being1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 10mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
MOTS-C 10mg
Summary Description: MOTS-c (Mitochondrial ORF of the 12S rRNA type c) is a mitochondrial-derived peptide that plays a vital role in regulating metabolism, energy balance, and cellular stress responses. Discovered in 2015, MOTS-c functions as a signaling molecule that helps the body respond to metabolic stress by improving glucose uptake, enhancing insulin sensitivity, and promoting fat metabolism. It acts as a mitochondrial messenger that communicates with the nucleus to maintain cellular homeostasis, making it a promising target for research on metabolic health, exercise performance, and healthy aging1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
TB-500 10mg
Summary Description: TB-500 is a synthetic heptapeptide analog of the actin-binding motif of thymosin ?4 (T?4), composed of the acetylated sequence Ac-LKKTETQ. This fragment conserves the principal bioactive domain associated with T?4’s regenerative activity. TB-500 has been shown to promote cell migration, angiogenesis, cytoskeletal reorganization, and anti-inflammatory signaling in preclinical models1,2. Due to its shorter sequence, TB-500 offers enhanced metabolic stability and amenability to synthetic optimization compared to the parent protein. While TB-500 is banned in competitive sports, it continues to be studied for its potential in promoting angiogenesis, tissue repair, and modulation of actin-binding proteins.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 20mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Testagen 20mg
Summary Description: Testagen is a synthetic, short peptide bioregulator that targets the regulation and restoration of testicular and endocrine system functions. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it has been shown in research models to stimulate protein synthesis in testicular cells, modulate gene expression linked to steroidogenesis, influence stem cell differentiation into functional Leydig-lineage cells, and counteract age-related involution of reproductive tissues. By binding to specific DNA sequences and protecting promoter regions from methylation, Testagen helps to maintain transcriptional activity in genes involved in hormone synthesis, with potential implications for sustaining optimal testosterone production under physiological stress or aging conditions1-3.
Products will arrive in a lyophilized (powder) form for maximum stability